Archon
Seattle, US · 12 known investors
Archon Biosciences develops a computational protein design platform leveraging AI and deep learning for therapeutic and vaccine applications. The company was founded in 2023 by James Lazarovits and George Ueda, Ph.D., building on research in AI-driven protein engineering and nanomaterial delivery.
AI & Machine LearningBiotechDeep Tech
Founders & leadership
Investors · 12
Cornucopian Capital ManagementMontclair
Madrona Venture GroupSeattle · $2M – $10M
Gaorong Capitalreported · 2 sourcesBeijing
Gaorong VenturesreportedGeorge Town, Grand Cayman · $2.8M – $120M
Gobi Partnersreported · 2 sourcesHong Kong · $709K – $37M
IDG Capitalreported · 2 sourcesHong Kong · $3M – $200M
Y CombinatorreportedSan Francisco · $500K
ZhenFundreported · 2 sourcesBeijing · $425K – $28M
Also in the syndicate · 4
5Y CapitalMiraclePlusShanghai Institute for Advanced Study of AIShanghai Zhiyuan Academy
Funding
SEC filings, press & company announcements- Undisclosed amountseed roundJun 2026 · 3 sources
5Y Capital, Gaorong Capital, Gaorong Ventures, Gobi Partners, IDG Capital, MiraclePlus, Shanghai Institute for Advanced Study of AI, Shanghai Zhiyuan Academy, ZhenFund
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 3
by search overlapCreyon18 shared keywordsCreyon develops cell-specific therapeutics using aptamer-delivered oligonucleotides and other payloads (lipid nanoparticles, nucleic acids) for immune-driven diseases, CNS conditions, and genetic disorders. The company combines proprietary aptamer delivery technology with an AI-powered nucleic acid engineering platform to enable targeted therapeutic delivery.
Regeneron NASDAQ: REGN www.regeneron.com17 shared keywordsRegeneron is a biopharmaceutical company that develops medicines ranging from biologics to genetic medicines for people with serious diseases across areas such as metabolic disease, ophthalmology, and rare diseases. It runs research and development programs and clinical trials aimed at treating conditions including generalized myasthenia gravis.
Orca Bio17 shared keywordsOrca Bio develops allogeneic T-cell immunotherapies for high-risk blood cancers including acute myeloid leukemia, acute lymphocytic leukemia, and myelodysplastic syndrome. The company is advancing precision cell therapy treatments for patients with blood cancers and autoimmune diseases.
Companies competing with Archon for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Archon do?
- Archon Biosciences develops a computational protein design platform leveraging AI and deep learning for therapeutic and vaccine applications. The company was founded in 2023 by James Lazarovits and George Ueda, Ph.D., building on research in AI-driven protein engineering and nanomaterial delivery.
- Who founded Archon?
- Archon was founded by George Ueda, Ph.D., James Lazarovits, Ph.D., James Lazarovits, George Ueda.
- Who are Archon's investors?
- Archon's investors include Cornucopian Capital Management, Madrona Venture Group, Gaorong Capital, Gaorong Ventures, Gobi Partners, IDG Capital, Y Combinator, ZhenFund.
- Where is Archon headquartered?
- Archon is headquartered in Seattle, US.